Article Information
History
- October 27, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- D. Puigoriol-Illamola1,2,
- J. Companys-Alemany1,2,
- N. Homer3,
- R. Leiva4,
- S. Vázquez4,
- D. Mole5,
- C. Griñán-Ferré1,2 and
- M. Pallàs1,2,*
- 1Department of Pharmacology, Toxicology and Therapeutic Chemistry. Pharmacology Section. Faculty of Pharmacy and Food Sciences. University of Barcelona, Av Joan XXIII 27-31, 08028 Barcelona, Spain
- 2Institute of Neuroscience, University of Barcelona (NeuroUB), Passeig de la Vall d’Hebron 171, Barcelona, Spain
- 3Mass Spectrometry Core, Edinburgh Clinical Research Facility, Queen’s Medical Research Institute, Edinburgh, United Kingdom
- 4Medicinal Chemistry Section. Department of Pharmacology, Toxicology and Therapeutic Chemistry. Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain
- 5MRC Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom
- ↵*Corresponding author: pallas{at}ub.edu
Posted October 27, 2020.
RL-118 and 11β-HSD1 target engagement through TAPS assay: behaviour and molecular analysis
